Overview
NICE is unable to make a recommendation on duvelisib (Copiktra) for treating relapsed follicular lymphoma after 2 or more systemic therapies in adults because Secura Bio has not provided an evidence submission.
Last reviewed: 21 July 2021
Next review: We will review this decision if the company decides to make a submission.